|
|
Addressing Challenges in Diagnosis and Treatment of Low-Grade Upper Tract Urothelial Carcinoma
OVERVIEW
Upper tract urothelial carcinoma (UTUC) has many similarities to bladder carcinoma, but also some important differences. Join Dr. Seth Lerner, as he contrasts these 2 diseases, as well as important differences between low-grade and high-grade UTUC. Dr. Lerner highlights important considerations in the instruments, imaging, and biopsy techniques for diagnosing low-grade UTUC. Surgical options are considered, with a focus on patient selection for endoscopic nephron-sparing surgery. The... |
|
Video Viewpoint Strategy Session: Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer
Learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Start the activity now!
STATEMENT OF NEED
There are an estimated 13,800 new c... |
|
|
Podcast: Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer
In this episode of Oncology Data Advisor TM, learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Listen now!
STATEMENT OF NEED
Th... |
|
Advanced Ovarian Cancer and PARP Inhibitors: Clinical Insights and Impact on New Data
In this CME activity, Susana M. Campos, MD, MS, MPH, reviews some of the recent clinical developments in the treatment of patients with advanced ovarian cancer with PARP inhibitors. We welcome you to learn more about the updated data from key clinical studies of PARP inhibitor maintenance therapy in advanced ovarian cancer, and the implications of the results on the current and emerging concepts in ovarian cancer clinical practice.
CONTENT AREAS
• Platinum-sensitive recurrent ovarian cance... |
|
|
Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies
Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity ... |
|
|
Video Viewpoint Strategy Session: Optimizing Treatment and Functional Outcomes in Head and Neck Squamous Cell Carcinoma
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Start the activity now.
STATEMENT OF NEED
H... |
|
|
Applying Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer
STATEMENT OF NEED
Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages (ACS, 2021).... |
|
Infusing Renewed Hope into Cancer-related Anemia with Intravenous Iron: AN EXPERT-LED EXPLORATION OF RECENT AND EMERGING TRIAL DATA AND CURRENT GUIDELINE RECOMMENDATIONS
Designed and developed to maximize digital audience reach and engagement, this Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundat... |
|
|
Video Viewpoint Strategy Session: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now.
STATEMENT OF NEED
Squamous ce... |
|
|
Podcast: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now.
STATEMENT OF NEED
Squamous ce... |
|
|
Improving Outcomes in Hodgkin Lymphoma
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now.
STATEMENT OF NEED
Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ... |
|
|
Updates in Myelodysplastic Syndromes: Improving Patient Outcomes
This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now.
STATEMENT OF NEED
Myelodysplastic syndromes (MDS) comprise a heterogeneous group ofmyeloid malignanciesthat derive from abnormal multipot... |
|
Research Highlights on Pyruvate Kinase (PK) Deficiency
This accredited CME activity provides a summary of the latest information about Pyruvate kinase (PK) deficiency that was presented at the 2021 American Society of Hematology Annual Meeting (ASH 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ASH 2021 and discuss this latest research, this program provides a review by Rachael Grace, MD, of the most clinically-relevant information on PK deficiency presented during the meeting.
PK deficiency is a rare genetic b... |
|
|
Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer
This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. ... |
|
|
Podcast: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer
This expert-led episode of Oncology Data Advisor TM, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non... |
|
|
Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.
STATEMENT OF NEED
Chemotherapy-induced neutropenia (CIN) is a potent... |
|
|
Podcast: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia
Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.
STATEMENT OF NEED
Chemotherapy-induced neutropenia (CIN) is a potent... |
|
|
Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer
Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine. Start the activity now!
... |
|
|
Podcast: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer
This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of adv... |
|
|
Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis
Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now!
STATEMENT OF NEED
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bon... |
|
|
Strategies for PD-L1 Testing and Targeted Therapy With Immune Checkpoint Inhibitors for NSCLC
Target Audience
Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists.
Program Overview
Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-re... |
|
|
PD-L1 Testing for NSCLC
Target Audience
Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists.
Program Overview
Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-re... |
|
|
Clinical Efficacy of Current Available and Investigational ICIS for NSCLC
Target Audience
Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists.
Program Overview
Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-re... |
|
|
Clinical Safety of Current Available and Investigational ICIS for NSCLC
Target Audience
Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists.
Program Overview
Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-re... |
|
|
New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy
Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC. During their presentations and discussion, they will examine the established treatment landscape for unresectable, stage III NSCLC as well as the emerging role of immunotherapy, and practical clinical considerations for anticipating, mitigating, and managing immune-related adverse events. |
|
|
RCC Treatment Strategies in a Poor-Risk Patient
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and dis... |
|
|
Clinical Compendium: Metastatic Squamous Non-Small Cell Lung Cancer
Target Audience
This activity is intended for a national audience of oncologists, nurse practitioners, nurses, physician assistants, and other clinicians.
Program Overview
CONTENT AREAS
Squamous NSCLC pathobiology, clinical behavior, and histopathologic subtyping
Biomarker testing in advanced squamous NSCLC
Recent changes to the NCCN guidelines regarding molecular testing
Therapeutic options for frontline treatment based on molecular testing results
Optimizing treatment
Managem... |
|
|
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multiple Myeloma
Discover new developments in sequential treatment and clinical findings, evaluate strategies to manage and monitor adverse events, and initiating therapy for patients with relapsed/refractory Multiple Myeloma, and much more! Leading oncologist Shaji Kumar, Mayo Clinic Cancer Center, presents this in-depth discussion. Start the activity now!
STATEMENT OF NEED
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramed... |
|
|
Intensive Review of Nephrology - LIVE STREAMING
With over 70 interactive lectures, case discussions, board preparation sessions, and supplementary lectures, this CME program provides a comprehensive review of state-of-the-art nephrology practices offered by the clinical faculty of Harvard Medical School. It is among the highest-rated HMS CME courses.
It offers accelerated learning for:
► Clinicians seeking a practical and comprehensive review that ensures they are up to date across all major areas of nephrology:
• The latest optio... |
|
|
RCC Treatment Strategies in a Favorable-Risk Patient
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize o... |
|
|
Medical Marijuana Certification Course-- Pennsylvania
The Medical Marijuana Certification Course has been approved by the Pennsylvania Board of Health as meeting the CME requirements necessary for physicians to participate in the Pennsylvania Medical Marijuana Program. This activity will help Pennsylvania physicians make informed decisions regarding medicinal cannabis treatments for their patients. It provides an evidence based analysis of marijuana’s efficacy, risks and benefits in treating the Pennsylvania list of approved conditions. The sc... |
|
|
Patient Perspectives and Clinical Updates on Somatostatin Receptor-Positive Neuroendocrine Tumors
Target Audience
The intended audience for this activity program are medical oncologists, endocrinologists, radiation oncologists, nuclear-medicine physicians and technologists, surgical oncologists, interventional radiologists, internists, nurses, nurse practitioners, and physician assistants managing patients with NETs.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Summarize the clinical characteristics and key aspects of a diagnosis ... |
|
|
Paradigm Shifts and Point-of-Care Decisions for Better Control of Urothelial Carcinoma/Bladder Cancer
Target Audience
This activity is intended for genitourinary and medical oncologists, urologists, oncology advanced practice providers, oncology nurses, internists, primary care physicians, and other clinicians interested/involved in the management of patients with bladder cancer.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Redefining the ‘Best’ Treatment Option for Patients with UTUC
Explain how to use histology to identify low-grad... |
|
|
Paradigm Shifts and Point-of-Care Decisions for Better Control of Urothelial Carcinoma/Bladder Cancer
Target Audience
This activity is intended for genitourinary and medical oncologists, urologists, oncology advanced practice providers, oncology nurses, internists, primary care physicians, and other clinicians interested/involved in the management of patients with bladder cancer.
Learning Objectives
Upon completion of this activity, participants should be better able to:
A Stratified Approach to Managing NMIBC with Surgical vs Non-Surgical Options
Assess recent safety and efficacy dat... |
|
|
INTERCEPT: IdeNTifying and Managing CancER Treatment CardiotoxicitiEs in Patients Undergoing Therapy
Target Audience
This activity is intended for nationally, regionally, and locally based oncology and cardiology physicians, advanced practice nurses, PAs, nurses, pharmacists and other healthcare professionals who are involved in the management of patients undergoing cancer treatment.
Program Overview
The educational goal of this activity is to provide healthcare professionals with knowledge and strategies to identify areas for improvement in the assessment and management of patients at r... |
|
|
7-Night St. Lucia CME AWAY® Resort - Forensic Dentistry, Domestic Violence, Oral Cancer and HPV and Psychiatric Illness and Dentistry: Challenges for Oral Care
Pigeon Island Gros Islet, St. Lucia
An idyllic all-inclusive resort located on its very own peninsula, Sandals Grande St. Lucian is often described as the “closest vacation to a picture-perfect postcard.” Cradled to the west by Rodney Bay – boasting the calmest waters in all of Saint Lucia – and to the east by the majestic Atlantic Ocean, this magnificent adults-only resort showcases awe-inspiring panoramic views and Over-The-Water Bungalows that will linger in your heart forever. V... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLL
Target Audience The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL. Learning Objectives Upon completion of this activity, participants should be better able to: Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies List the emerging combination regimens, including BTK inhi... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Patient Selection
Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
List the emerging combination regimens, including... |
|
|
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Aligning Patient and Provider Goals
Target Audience
The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
List the emerging combination regimens, including... |
|
|
Improving the Prognosis for Patients with BRAF-Mutant and/or MSI-H mCRC
Are you current with the latest updates with MSI-H/dMMR and/or BRAF-mutant metastatic colorectal cancer? In this case-based activity, leading expert and researcher, Dr. Dung Le discusses the latest approvals and recommendations for patients with MSI-H/dMMR and/or BRAF-mutant mCRC. This activity also features interactive case presentations which involve biomarker testing, treatment selection, and mitigating potential adverse events. |
|
|
Update in Clinical Cardiology - LIVE STREAMING or IN PERSON
The Comprehensive Clinical Cardiology Update
Evaluation • Treatment • Patient Care • Procedures • Challenging Cases
Update in Clinical Cardiology will be held on October 12 " 14, 2022. You have the option to attend either online as the course is live streamed or in person in Boston, MA.
This program, which is among the highest-rated Harvard Medical School CME courses, provides a comprehensive review of state-of-the-art practices to diagnose and treat patients with cardio... |
|
|
Follicular Lymphoma: Answers to Important Nursing Questions
Target Audience
This activity is designed to meet the educational needs of oncology nurses, nurse practitioners and navigators engaged in the care of patients with follicular lymphoma.
Program Overview
Advances in the treatment of FL have led to the approval of two novel agents as well as updates to clinical practice guidelines. Oncology nursing professionals have unique and often long-standing relationships with their FL patients and are trusted sources of information and support. Th... |
|
|
Through the Patient/Family Looking Glass: Perspectives in Treatment Planning by Disease Compartments for Pediatric Neuroblastoma
Target Audience
The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.
Statement of Need/Program Overview
With an ever-improving understanding of clinical and biological risk factors, treatment strategies for pediatric neuroblastoma have become more... |
|
|
Primary Care Internal Medicine - LIVE STREAMING
The Comprehensive Primary Care Update
Updates Across All Major Areas of Primary Care and Guidance to Incorporate Them into Practice for State-of-the-Art Patient Care
This highly rated Harvard Medical School CME program provides a comprehensive update of the most important changes and advances impacting primary care and guidance to incorporate them into everyday clinical practice. Speakers are among the top clinician-educators at Harvard Medical School.
State-of-the-art approaches to the... |
|
|
Update in Hospital Medicine 2022 - LIVE STREAMING
Update in Hospital Medicine will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies.
This 4-day intensive Harvard Medical School CME program updates busy practitioners on current, best practices in hospital medicine. Among the highest-rated HMS CME courses, it covers over 30 core topics, with an emphasis on practical management of common problems:
• COVID-19
• Health equity/vulnerable populations
• Heart failure
• Atrial fibril... |
|
|
Podcast: Applying Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer
STATEMENT OF NEED
Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages (ACS, 2021).... |
|
|
OCN® Exam Review (Live Webinar) - Miami, FL
Course Description
This program is designed for oncology nurses seeking a general oncology review in preparation for the ONCC® OCN Exam. We will focus on the following categories from the 2018 OCN blueprint: cancer continuum, oncology nursing practice, cancer treatment modalities, symptom management, palliative care, oncologic emergencies and psychosocial dimensions of care. This is not meant to be an introductory course, but rather a comprehensive review of basic oncology nursing practice.
... |
|
|
Interprofessional Perspectives on Managing Immune-Related Adverse Events
The development of immunotherapies, including ICIs and CAR-T cell agents, is improving survival for some patients with cancer, even in advanced cases. These agents are associated with novel irAEs that are monitored and managed differently than the more familiar standard chemotherapy toxicities. Collaboration among members of the oncology care team is necessary to ensure that all healthcare providers, patients, and caregivers are educated about irAEs and their management. For all members of the... |
|
|
Interprofessional Perspectives on Managing Immune-Related Adverse Events
Target Audience
This activity will reach the interprofessional care team of physicians, nurses and pharmacists who care for patients undergoing immunotherapy treatments.
Program Overview
The development of immunotherapies, including ICIs and CAR-T cell agents, is improving survival for some patients with cancer, even in advanced cases. These agents are associated with novel irAEs that are monitored and managed differently than the more familiar standard chemotherapy toxicities. Collaborat... |
|
|
Monoclonal Antibodies in the Treatment of at Risk Patients With COVID-19 to Reduce Hospitalization and Severe Disease
EXPLORE educational module with highly interactive and engaging online content, designed to allow learners to traverse non-linearly, depending on their educational needs and interests.
• Review the utility of monoclonal antibodies use for the management of at risk patients with COVID-19, including variants
• Explain how management of COVID-19 with monoclonal antibodies affects viral load
• Recognize specific IDSA and NIH guideline-recommended treatments for at risk, select appropriate... |
|